Humana Inc vs MobilEye Global Inc — how do they compare? Humana Inc trades at $437.41 (market cap $47.61B), while MobilEye Global Inc trades at $7.04 (market cap $6.08B). The key difference: Humana Inc is far larger — about 7.8× MobilEye Global Inc's market cap, and Humana Inc pays a 0.89% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and MobilEye Global Inc for 15 Days on average.
| HUM | MBLY | |
|---|---|---|
Market Cap | $47.61B | $6.08B |
Volume | 1,827,332 | 4,250,290 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $15.42 |
52-Week Low | $163.67 | $6.56 |
Typical Hold Time | 53 Days | 15 Days |
Enterprise Value | $54.97B | $4.64B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Mobileye Global (MBLY) trades at $7.15, down 4.28% amid bearish technical signals, though RSI levels suggest potential oversold conditions. The company shows mixed fundamentals with strong revenue growth to $2.0B in 2026 but deep losses (-$4.1B net income). Analyst consensus remains positive with 57.7% buy ratings and $10.83 price target, while recent news highlights ADAS business momentum and autonomous vehicle expansion initiatives.
MBLY presents a high-risk opportunity with significant upside potential if execution improves, but current profitability challenges and bearish technicals warrant caution. The stock trades below book value (P/B 0.74) with institutional confidence shown through recent insider buying, though competitive pressures in autonomous driving and ongoing losses represent substantial investor risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →